PhoenixBio Co., Ltd. (6190.T)
JPY 324.0
(1.25%)
JPY 324.0
(1.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.71 Billion JPY | -10.05% |
| 2022 | 3.01 Billion JPY | 32.37% |
| 2021 | 2.28 Billion JPY | -9.37% |
| 2020 | 2.51 Billion JPY | -9.63% |
| 2019 | 2.78 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.75 Billion JPY | 1.42% |
| 2023 Q4 | 2.71 Billion JPY | 0.65% |
| 2023 Q3 | 2.69 Billion JPY | -15.07% |
| 2023 Q1 | 3.06 Billion JPY | 1.62% |
| 2023 Q2 | 3.17 Billion JPY | 3.55% |
| 2023 FY | 2.71 Billion JPY | -10.05% |
| 2022 Q3 | 2.71 Billion JPY | 1.36% |
| 2022 Q2 | 2.67 Billion JPY | 0.0% |
| 2022 Q4 | 3.01 Billion JPY | 11.27% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 58.792% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -124.142% |
| GNI Group Ltd. | 62.39 Billion JPY | 95.648% |
| Linical Co., Ltd. | 18.53 Billion JPY | 85.354% |
| Trans Genic Inc. | 9.81 Billion JPY | 72.324% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 51.806% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 60.909% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 53.316% |
| AnGes, Inc. | 28.89 Billion JPY | 90.602% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -213.086% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.273% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -67.759% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 46.457% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 37.577% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -11.61% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -14.408% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 60.819% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -55.032% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 46.607% |
| PeptiDream Inc. | 67.12 Billion JPY | 95.955% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -33.065% |
| Ribomic Inc. | 3.54 Billion JPY | 23.453% |
| SanBio Company Limited | 5.04 Billion JPY | 46.202% |
| Healios K.K. | 15.15 Billion JPY | 82.083% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -120.712% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 9.969% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -84.195% |
| StemRIM | 9.08 Billion JPY | 70.096% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 60.532% |
| FunPep Company Limited | 2.49 Billion JPY | -8.999% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -3.691% |
| Stella Pharma Corporation | 3.82 Billion JPY | 28.93% |
| TMS Co., Ltd. | 3.55 Billion JPY | 23.614% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 53.014% |
| Cuorips Inc. | 6.18 Billion JPY | 56.096% |
| K Pharma,Inc. | 3.31 Billion JPY | 18.063% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.796% |
| ReproCELL Incorporated | 9.05 Billion JPY | 70.005% |
| StemCell Institute Inc. | 6.54 Billion JPY | 58.501% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 61.147% |
| CellSeed Inc. | 2.46 Billion JPY | -10.121% |